The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia

Seminars in Hematology

Volumn 51, Issue 3, 2014, Pages 158-167

  Stevenson, Freda K ^a   Forconi, Francesco ^a   Packham, Graham ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; PROTEIN KINASE INHIBITOR; SUPERANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CELL FATE; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLONAL ANERGY; DOWN REGULATION; EVIDENCE BASED MEDICINE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC CONSERVATION; GENETIC VARIABILITY; GERMINAL CENTER; HUMAN; IGHV GENE; IGHV HD HJ GENE; IGHV1 69 GENE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION; STEREOTYPY; TREATMENT RESPONSE;

B-LYMPHOCYTES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 84904429647     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.05.003     Document Type: Article

References (92)

1. Rossi D., Sozzi E., Puma A., Forconi F. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009, 146:64-75.
2. Ghia P., Caligaris-Cappio F. Monoclonal B-cell lymphocytosis: right track or red herring?. Blood 2012, 119:4358-4362.
3. Roulland S., Faroudi M., Mamessier E., Sungalee S., Salles G., Nadel B. Early steps of follicular lymphoma pathogenesis. Adv Immunol 2011, 111:1-46.
4. Nicoloso M.S., Kipps T.J., Croce C.M., Calin G.A. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 2007, 139:709-716.
5. Krober A., Seiler T., Benner A., Bullinger L., Bruckle E., Lichter P., et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100:1410-1416.
6. Knight S.J., Yau C., Clifford R., Timbs A.T., Sadighi Akha E., Dreau H.M., et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 2012, 26:1564-1575.
7. Davids M.S., Brown J.R. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53:2362-2370.
8. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
9. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
10. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
11. Ten Hacken E., Burger J.A. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia-focus on the B-cell receptor. Clin Cancer Res 2014, 20:548-556.
12. Mockridge C.I., Potter K.N., Wheatley I., Neville L.A., Packham G., Stevenson F.K. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109:4424-4431.
13. Joly E., Hudrisier D. What is trogocytosis and what is its purpose?. Nat Immunol 2003, 4:815.
14. Duhren-von Minden M., Ubelhart R., Schneider D., Wossning T., Bach M.P., Buchner M., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489:309-312.
15. Damle R.N., Calissano C., Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol 2010, 23:33-45.
16. Herishanu Y., Perez-Galan P., Liu D., Biancotto A., Pittaluga S., Vire B., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117:563-574.
17. Igawa T., Sato Y., Takata K., Fushimi S., Tamura M., Nakamura N., et al. Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Sci 2011, 102:2103-2107.
18. Krysov S., Dias S., Paterson A., Mockridge C.I., Potter K.N., Smith K.C., et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood 2012, 119:170-179.
19. Coelho V., Krysov S., Steele A., Sanchez Hidalgo M., Johnson P.W., Chana P.S., et al. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood 2013, 122:2664-2672.
20. Calissano C., Damle R.N., Marsilio S., Yan X.J., Yancopoulos S., Hayes G., et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med 2011, 17:1374-1382.
21. Brown J.R. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma 2014, 55:263-269.
22. Davids M.S., Brown J.R. Phosphoinositide 3[U+05F3]-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013, 27:329-339.
23. Packham G., Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010, 20:391-399.
24. Petlickovski A., Laurenti L., Li X., Marietti S., Chiusolo P., Sica S., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105:4820-4827.
25. Paterson A., Mockridge C.I., Adams J.E., Krysov S., Potter K.N., Dunscombe M.S., et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 2012, 119:1726-1736.
26. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
27. Lanham S., Hamblin T., Oscier D., Ibbotson R., Stevenson F., Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003, 101:1087-1093.
28. Davids M.S., Burger J.A. Cell trafficking in chronic lymphocytic leukemia. Open J Hematol 2012, 3:pii.
29. Yarkoni Y., Getahun A., Cambier J.C. Molecular underpinning of B-cell anergy. Immunol Rev 2010, 237:249-263.
30. Duty J.A., Szodoray P., Zheng N.Y., Koelsch K.A., Zhang Q., Swiatkowski M., et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009, 206:139-151.
31. Tavolaro S., Peragine N., Chiaretti S., Ricciardi M.R., Raponi S., Messina M., et al. IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. Leuk Res 2013, 37:455-462.
32. Quiroga M.P., Balakrishnan K., Kurtova A.V., Sivina M., Keating M.J., Wierda W.G., et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114:1029-1037.
33. Vlad A., Deglesne P.A., Letestu R., Saint-Georges S., Chevallier N., Baran-Marszak F., et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res 2009, 69:6387-6395.
34. Apollonio B., Scielzo C., Bertilaccio M.T., Ten Hacken E., Scarfo L., Ranghetti P., et al. Targeting B-cell anergy in chronic lymphocytic leukemia. Blood 2013, 121(3879-88):S1-S8.
35. Ng Y.S., Wardemann H., Chelnis J., Cunningham-Rundles C., Meffre E. Bruton[U+05F3]s tyrosine kinase is essential for human B cell tolerance. J Exp Med 2004, 200:927-934.
36. Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30:488-496.
37. Lam K.P., Kuhn R., Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997, 90:1073-1083.
38. Kraus M., Alimzhanov M.B., Rajewsky N., Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004, 117:787-800.
39. Johnson T.A., Rassenti L.Z., Kipps T.J. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997, 158:235-246.
40. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
41. Jung D., Giallourakis C., Mostoslavsky R., Alt F.W. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol 2006, 24:541-570.
42. Brezinschek H.P., Foster S.J., Brezinschek R.I., Dorner T., Domiati-Saad R., Lipsky P.E. Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J Clin Invest 1997, 99:2488-2501.
43. Dorner T., Lipsky P.E. Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity. Clin Exp Med 2005, 4:159-169.
44. Pascual V., Victor K., Spellerberg M., Hamblin T.J., Stevenson F.K., Capra J.D. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol 1992, 149:2337-2344.
45. Potter K.N., Hobby P., Klijn S., Stevenson F.K., Sutton B.J. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen. J Immunol 2002, 169:3777-3782.
46. Li Y., Spellerberg M.B., Stevenson F.K., Capra J.D., Potter K.N. The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. J Mol Biol 1996, 256:577-589.
47. Spellerberg M.B., Chapman C.J., Mockridge C.I., Isenberg D.A., Stevenson F.K. Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: a possible link between infection and lupus. Hum Antibodies Hybridomas 1995, 6:52-56.
48. Thompsett A.R., Ellison D.W., Stevenson F.K., Zhu D.V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 1999, 94:1738-1746.
49. Montesinos-Rongen M., Roers A., Kuppers R., Rajewsky K., Hansmann M.L. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin[U+05F3]s disease. Blood 1999, 94:1755-1760.
50. Silverman G.J., Goodyear C.S. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 2006, 6:465-475.
51. Kipps T.J., Tomhave E., Pratt L.F., Duffy S., Chen P.P., Carson D.A. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1989, 86:5913-5917.
52. Murray F., Darzentas N., Hadzidimitriou A., Tobin G., Boudjogra M., Scielzo C., et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008, 111:1524-1533.
53. Widhopf G.F., Goldberg C.J., Toy T.L., Rassenti L.Z., Wierda W.G., Byrd J.C., et al. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood 2008, 111:3137-3144.
54. Ghiotto F., Fais F., Albesiano E., Sison C., Valetto A., Gaidano G., et al. Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. Mol Med 2006, 12:300-308.
55. Messmer B.T., Albesiano E., Efremov D.G., Ghiotto F., Allen S.L., Kolitz J., et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004, 200:519-525.
56. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
57. Agathangelidis A., Darzentas N., Hadzidimitriou A., Brochet X., Murray F., Yan X.J., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012, 119:4467-4475.
58. Forconi F., Potter K.N., Wheatley I., Darzentas N., Sozzi E., Stamatopoulos K., et al. The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010, 115:71-77.
59. Seifert M., Sellmann L., Bloehdorn J., Wein F., Stilgenbauer S., Durig J., et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012, 209:2183-2198.
60. Capolunghi F., Rosado M.M., Sinibaldi M., Aranburu A., Carsetti R. Why do we need IgM memory B cells?. Immunol Lett 2013, 152:114-120.
61. Link A., Zabel F., Schnetzler Y., Titz A., Brombacher F., Bachmann M.F. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol 2012, 188:3724-3733.
62. Lanemo Myhrinder A., Hellqvist E., Sidorova E., Soderberg A., Baxendale H., Dahle C., et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008, 111:3838-3848.
63. Landgren O., Rapkin J.S., Caporaso N.E., Mellemkjaer L., Gridley G., Goldin L.R., et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 2007, 109:2198-2201.
64. Steininger C., Widhopf G.F., Ghia E.M., Morello C.S., Vanura K., Sanders R., et al. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood 2012, 119:2293-2301.
65. Meffre E., Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008, 20:632-638.
66. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003, 9:736-743.
67. Catera R., Silverman G.J., Hatzi K., Seiler T., Didier S., Zhang L., et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008, 14:665-674.
68. Que X., Widhopf G.F., Amir S., Hartvigsen K., Hansen L.F., Woelkers D., et al. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One 2013, 8:e65203.
69. Widhopf G.F., Rassenti L.Z., Toy T.L., Gribben J.G., Wierda W.G., Kipps T.J. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004, 104:2499-2504.
70. Chu C.C., Catera R., Zhang L., Didier S., Agagnina B.M., Damle R.N., et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010, 115:3907-3915.
71. Forconi F., Potter K.N., Sozzi E., Henderson I., Cencini E., Rossi D., et al. The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. Blood 2012, 119:2106-2109.
72. Kienle D., Benner A., Krober A., Winkler D., Mertens D., Buhler A., et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006, 107:2090-2093.
73. Panovska-Stavridis I., Ivanovski M., Siljanovski N., Cevreska L., Efremov D.G. Chronic lymphocytic leukemia patients with a V1-69 gene rearrangement do not have inferior survival with respect to patients that express other unmutated V(H) genes. Leuk Res 2007, 31:245-248.
74. Strefford J.C., Sutton L.A., Baliakas P., Agathangelidis A., Malčíková J., Plevova K., et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013, 27:2196-2199.
75. Rossi D., Spina V., Bomben R., Rasi S., Dal-Bo M., Bruscaggin A., et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood 2013, 121:4902-4905.
76. Herve M., Xu K., Ng Y.S., Wardemann H., Albesiano E., Messmer B.T., et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005, 115:1636-1643.
77. Fais F., Ghiotto F., Hashimoto S., Sellars B., Valetto A., Allen S.L., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102:1515-1525.
78. Dal-Bo M., Del Giudice I., Bomben R., Capello D., Bertoni F., Forconi F., et al. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. Br J Haematol 2011, 153:3-14.
79. Stevenson F.K., Smith G.J., North J., Hamblin T.J., Glennie M.J. Identification of normal B-cell counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br J Haematol 1989, 72:9-15.
80. Potter K.N., Mockridge C.I., Neville L., Wheatley I., Schenk M., Orchard J., et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006, 12:1672-1679.
81. Parikh S.A., Rabe K.G., Kay N.E., Call T.G., Ding W., Schwager S.M., et al. Chronic lymphocytic leukemia in young (<= 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica 2014, 99:140-147.
82. Chapman C.J., Spellerberg M.B., Hamblin T.J., Stevenson F.K. Pattern of usage of the VH4-21 gene by B lymphocytes in a patient with EBV infection indicates ongoing mutation and class switching. Mol Immunol 1995, 32:347-353.
83. Kostareli E., Hadzidimitriou A., Stavroyianni N., Darzentas N., Athanasiadou A., Gounari M., et al. Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 2009, 23:919-924.
84. Cahill N., Sutton L.A., Jansson M., Murray F., Mansouri L., Gunnarsson R., et al. IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2012, 12:201-206.
85. Tobin G., Thunberg U., Johnson A., Eriksson I., Soderberg O., Karlsson K., et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003, 101:4952-4957.
86. Bomben R., Dal Bo M., Capello D., Benedetti D., Marconi D., Zucchetto A., et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood 2007, 109:2989-2998.
87. Hoogeboom R., van Kessel K.P., Hochstenbach F., Wormhoudt T.A., Reinten R.J., Wagner K., et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 2013, 210:59-70.
88. Rosen A., Murray F., Evaldsson C., Rosenquist R. Antigens in chronic lymphocytic leukemia-implications for cell origin and leukemogenesis. Semin Cancer Biol 2010, 20:400-409.
89. Hoogeboom R., Wormhoudt T.A., Schipperus M.R., Langerak A.W., Dunn-Walters D.K., Guikema J.E., et al. A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient. Leukemia 2013, 27:738-740.
90. Dighiero G., Hart S., Lim A., Borche L., Levy R., Miller R.A. Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood 1991, 78:581-585.
91. Majid A., Lin T.T., Best G., Fishlock K., Hewamana S., Pratt G., et al. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 2011, 35:750-756.
92. Pepper C. Unpublished data.